Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00056160 · ClinicalTrials.gov registry record · Phase 3
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 353
- Enrollment target
NCT00056160 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 353 participants.
The verdict
NCT00056160, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 353 participants
- Enrollment target
Study Summary
Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
Interventions
- DRUG Dexamethasone
- DRUG CC-5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2003-01-01 |
| Est. Completion | 2008-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00056160
The ClinicalTrials.gov registry entry for NCT00056160 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT00056160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00056160 about?
NCT00056160 is a clinical study titled "CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma". Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
What is the current status of trial NCT00056160?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 353 participants. The study started on 2003-01-01. Estimated completion is 2008-10-01.
What interventions are being tested in trial NCT00056160?
The interventions under investigation include: Dexamethasone (DRUG), CC-5013 (DRUG).
Who is sponsoring clinical trial NCT00056160?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.